A Controversial New Drug Treatment for Alzheimer Disease: What are the Concerns?

Event Date: February 10th, 2022

Developing treatments for Alzheimer's disease is challenging, with few effective therapies that only target symptoms. Aducanumab, sold under the brand name Aduhelm, is a medication designed to treat Alzheimer's disease. It is the newest clinical treatment for Alzheimer's in nearly twenty years. Although the US Food and Drug Administration (FDA) approved Aduhelm on June 7, 2021 — its approval was controversial.

Dr. Richard Sztramko

Geriatrician, Assistant Professor, McMaster University

Through his work with patients with dementia and their families, Dr. Sztramko came to understand that there is a desire and need for online education about dementia that has been developed by experts in geriatrics. This inspired him to pursue the creation of iGeriCare.

Dr. Anthony Levinson

Neuropsychiatrist, Director, Division of e-Learning Innovation, McMaster University

At the Division of e-Learning Innovation, Dr. Levinson exercises his passion for researching and developing online solutions to deliver high-quality health educational experiences to both the public and health care professionals. iGeriCare provides a unique opportunity to leverage his expertise in mental health and learning technologies to create a modern and engaging approach to dementia education.